Drug Profile
Roneparstat
Alternative Names: LB-401; SST 0001Latest Information Update: 08 Aug 2022
Price :
$50
*
At a glance
- Originator Sigma-Tau Pharmaceuticals
- Developer Leadiant Biosciences
- Class Antineoplastics; Heparins
- Mechanism of Action Angiogenesis inhibitors; Heparinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 26 Jul 2022 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in Italy, Israel, Germany (SC) (Leadiant Biosciences pipeline, July 2022)
- 26 Jul 2022 Discontinued - Phase-II for Multiple myeloma in USA (SC) (Leadiant Biosciences pipeline, July 2022)
- 28 Jul 2019 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in Germany (SC)